Estée Lauder Companies
EL
$98.05
+3.95%
The Estée Lauder Companies Inc. is a global leader in the prestige beauty market, operating across skin care (49% of fiscal 2025 sales), makeup (29%), fragrance (17%), and hair care and others (5%), with a portfolio that includes Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The company sells through department stores, travel retail, specialty beauty retailers, freestanding stores, e-commerce, salons/spas, and perfumeries in more than 150 countries, generating 31% of revenue from the Americas, 37% from EMEA (including travel retail), and 32% from Asia-Pacific. The current investor narrative centers on a credible turnaround: after a prolonged earnings slump driven by weak Asia travel retail and inventory destocking, recent quarters show accelerating sales and expanding margins, with the August 2026 fiscal Q4 report triggering a sharp positive stock reaction. The decision to walk away from merger talks with Puig in May 2026 was also welcomed by investors, who preferred clarity around an independent turnaround plan over deal uncertainty, reinforcing the market's focus on organic execution and margin recovery.…
EL
Estée Lauder Companies
$98.05
Related headlines
Investment Opinion: Should I buy EL Today?
Rating: Hold. The core thesis is that EL is a credible turnaround story with accelerating revenue and expanding margins, but the valuation already prices in much of the recovery, leaving a balanced risk/reward. The analyst consensus is 'buy' with a mean rating of 2.23 and an average target price of $107.34, implying 9.5% upside, which is modest relative to the stock's 1.265 beta and 32.5% downside to the 52-week low. Supporting evidence includes 6.33% YoY revenue growth in Q4 2026, gross margin expansion to 75.46%, $1.316 billion in trailing free cash flow, and a 1.78% dividend yield. However, the forward PE of 24.97x is above the sector median for consumer defensive stocks, and the trailing PE of 157.9x reflects how far earnings must recover to justify the price. The biggest risks are a renewed Asia-Pacific slowdown, a dividend cut due to the 279% payout ratio, and competitive share loss in skin care. The rating would upgrade to Buy if forward PE compresses below 20x or if Q1 2027 EPS exceeds $1.00, and downgrade to Sell if revenue growth decelerates below 3% or if gross margin falls below 73%. Relative to its own history and peers, EL appears fairly valued to slightly overvalued, with the market already discounting a successful turnaround.
Sign up to view all
EL 12-Month Price Forecast
The forward-looking view is balanced, with the base case (55% probability) targeting $100-$115 as the most likely outcome. The company's turnaround is real but fragile: revenue is growing, margins are expanding, and free cash flow is positive, yet the net loss in Q4 2026 and the unsustainable dividend payout highlight that the recovery is not yet self-sustaining. The stock's 1.265 beta and 32.5% downside to the 52-week low make it unsuitable for risk-averse investors. I would upgrade to bullish if Q1 2027 shows EPS above $1.00 and gross margin above 76%, and downgrade to bearish if revenue growth falls below 3% or if the dividend is cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Estée Lauder Companies's 12-month outlook, with a consensus price target around $107.34 and implied upside of +9.5% versus the current price.
Average Target
$107.34
0 analysts
Implied Upside
+9.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $127
Analyst target range
Bulls vs Bears: EL Investment Factors
The bull case currently has stronger evidence, driven by accelerating revenue growth (+6.33% YoY), a 346 basis point gross margin expansion, and a 16% single-day stock jump on the Q4 2026 earnings report. However, the bear case is not without merit: trailing PE of 157.9x, a 2.43x debt-to-equity ratio, and a 279% payout ratio highlight significant financial fragility. The single most important tension is whether the margin recovery can be sustained long enough to bring earnings in line with the $4.25 consensus EPS estimate, which would justify the forward PE of 24.97x. If Q4's net loss proves to be a one-time anomaly and margins hold above 75%, the bull case likely prevails; if not, the stock could retest its 52-week low of $66.22.
Bullish
- Turnaround momentum accelerating: Fiscal Q4 2026 revenue grew 6.33% year-over-year to $3.627 billion, a sharp reversal from the prior-year quarter's decline, and the stock jumped 16.2% on the August 19, 2026 report (from $84.27 to $98.01). This confirms the market is rewarding tangible execution on the turnaround plan.
- Gross margin expansion underway: Gross margin reached 75.46% in Q4 2026, up from 72.00% in Q4 2025, a 346 basis point improvement. The sequential trend is also positive, with Q3 2026 at 76.40% and Q2 2026 at 76.50%, indicating pricing power and a favorable mix shift toward higher-margin skin care and fragrance.
- Analyst consensus sees 9.5% upside: 28 analysts rate EL a 'buy' with a mean recommendation of 2.23 and an average target price of $107.34, implying 9.5% upside from the current $98.05. The high target of $127.00 suggests 29.5% upside if the turnaround exceeds expectations.
- Strong relative momentum vs. S&P 500: EL has outperformed the S&P 500 by 15.49 percentage points over the past 3 months and 20.34 points over 6 months, despite a -22.33 point YTD relative underperformance. This recent inflection suggests institutional accumulation is underway as the turnaround gains credibility.
Bearish
- Extreme trailing valuation metrics: The trailing PE ratio is 157.9x and the PEG ratio is -1.36, reflecting a near-zero trailing EPS of $0.006. Even the forward PE of 24.97x is rich for a company with a 1.21% net margin, leaving little room for execution missteps.
- High leverage constrains flexibility: Debt-to-equity stands at 2.43x, and the current ratio is only 1.22, indicating a tight liquidity position. Interest expense of $84 million in Q4 2026 alone consumes a significant portion of operating income, limiting reinvestment capacity.
- Asia-Pacific and travel retail exposure: With 32% of revenue from Asia-Pacific and 37% from EMEA (including travel retail), EL remains highly sensitive to Chinese consumer weakness and global travel disruptions. Any renewed destocking in these channels could quickly reverse the recent sales acceleration.
- Q4 2026 net loss despite revenue growth: Despite 6.33% revenue growth, EL reported a net loss of $116 million (-$0.32 EPS) in Q4 2026, driven by $358 million in other expenses and a $12 million tax expense. This shows that top-line recovery is not yet translating into bottom-line profitability.
EL Technical Analysis
Beta
1.26
1.26x market volatility
Max Drawdown
-43.8%
Largest decline past year
52-Week Range
$66-$122
Price range past year
Annual Return
+4.3%
Cumulative gain past year
| Period | EL Return | S&P 500 |
|---|---|---|
| 1m | -0.7% | +1.9% |
| 3m | +18.6% | +3.9% |
| 6m | +34.9% | +12.1% |
| 1y | +4.3% | +19.2% |
| ytd | -8.2% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EL Fundamental Analysis
Quarterly Revenue
$3.6B
2026-06
Revenue YoY Growth
+6.3%
YoY Comparison
Gross Margin
75.5%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EL Overvalued?
PE
157.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 31x~169x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. EL carries a debt-to-equity ratio of 2.43x and a current ratio of just 1.22, leaving limited liquidity buffer. The trailing twelve-month free cash flow of $1.316 billion is healthy, but the 279% payout ratio means the dividend consumes more cash than the company earns, and Q4 2026's $116 million net loss shows that profitability remains elusive. Additionally, 49% of sales come from skin care, creating product concentration risk if that category slows. Market and competitive risks are equally pressing. The stock trades at a forward PE of 24.97x and a price-to-book of 7.52x, a premium that assumes flawless execution. With a beta of 1.265, EL is 26.5% more volatile than the market, and its -22.33% YTD relative underperformance versus the S&P 500 highlights how quickly sentiment can sour. Competition from indie brands and mass-market beauty players continues to pressure pricing, while regulatory scrutiny on ingredients in the EU and China adds compliance costs. The worst-case scenario would involve a renewed slowdown in Asia-Pacific and travel retail, forcing another round of inventory destocking and a dividend cut. In that scenario, the stock could fall to its 52-week low of $66.22, representing a 32.5% decline from the current $98.05. If analyst bear-case targets of $70.00 are hit, the downside is 28.6%. A more severe outcome, such as a global recession combined with market share loss, could push the stock below $60, implying a loss of nearly 39% from current levels.
FAQ
The most severe risk is financial: debt-to-equity of 2.43x and a 279% payout ratio mean the dividend is at risk, and a cut could trigger a sharp sell-off. Second, operational risk: 49% of sales come from skin care, and 32% from Asia-Pacific, so a slowdown in either category or region would hit revenue hard. Third, competitive risk: indie brands and mass-market players are gaining share in prestige beauty, pressuring pricing and margins. Fourth, macro risk: with a beta of 1.265, EL is more volatile than the market, and a global recession could reduce discretionary spending on prestige beauty. These risks are ranked from most to least severe, with the dividend sustainability being the most immediate concern.
The 12-month forecast is based on three scenarios: a bull case (25% probability) targeting $115-$127, a base case (55% probability) targeting $100-$115, and a bear case (20% probability) targeting $66.22-$70.00. The base case is most likely, assuming revenue growth of 4-6% and EPS meeting the $4.25 consensus, which would support a stock price around the analyst average target of $107.34. The bull case requires faster margin expansion and successful new product launches, while the bear case assumes a renewed Asia-Pacific slowdown and a dividend cut. The key assumption behind the base case is that gross margins hold above 74.5% and that the Q4 2026 net loss was a one-time event.
EL appears fairly valued to slightly overvalued on a forward basis. The forward PE of 24.97x is above the typical 18-22x range for consumer defensive stocks, and the price-to-book of 7.52x is rich. The trailing PE of 157.9x is distorted by near-zero trailing EPS, but the PEG ratio of -1.36 reflects negative earnings growth expectations. The market is pricing in a successful turnaround, with EPS expected to recover to $4.25, which would bring the forward PE down to a more reasonable level. Compared to its own history, EL has traded at a premium during growth phases, but the current valuation leaves little margin for error. If the turnaround falters, the stock could see significant multiple compression.
EL is a reasonable buy for investors seeking exposure to a prestige beauty turnaround with a 2-3 year horizon, but it is not a low-risk investment. The stock trades at $98.05, with analyst targets averaging $107.34 (9.5% upside) and a high target of $127.00 (29.5% upside). However, the downside to the 52-week low of $66.22 is 32.5%, and the 1.265 beta means it will likely amplify market swings. The company's Q4 2026 revenue grew 6.33% YoY, but it posted a $116 million net loss, so the recovery is not yet proven. For risk-tolerant investors who believe in the margin recovery story, EL offers a favorable risk/reward at current levels, but conservative investors should wait for a pullback toward $85 or for clearer evidence of sustained profitability.
EL is better suited for long-term investment with a minimum holding period of 2-3 years, as the turnaround will take time to fully materialize. The stock's beta of 1.265 and 32.5% downside to the 52-week low make it too volatile for short-term trading unless one is actively hedging. The dividend yield of 1.78% is modest but provides some income, though the 279% payout ratio means it is not guaranteed. Earnings visibility is improving but still uncertain, with a wide analyst EPS range of $4.18 to $4.33. Short-term traders could exploit volatility around earnings, but long-term investors should focus on the margin recovery and Asia-Pacific growth story.